|
Brian Leyland-Jones, M.D., Ph.D. is currently Associate Vice President, Health Affairs and Director of the Winship Cancer Institute of the Emory University School of Medicine in Atlanta. He previously held the Minda de Gunzburg endowed chair in Oncology and was the founding Chair of the Department of Oncology at McGill University in Montreal, Canada. As founding Chair, he established the department and clinical trials operation with liaisons with over 40 pharmaceutical companies. He has spent the past 24 years dedicated to clinical pharmacology, oncology, and anti-viral drug development. Six of these years were spent at the prestigious Memorial Sloan-Kettering Cancer Center in New York (Phase I development therapeutic effort and laboratory, and defining new pharmacokinetic and pharmacodynamic biomarkers) and six years as Chief of the Developmental Chemotherapy section at the National Cancer Institute of the United States. Professor Leyland-Jones graduated from the University of London (Biochemistry, 1st class Honours) in 1970 and received his Bachelor of Medicine and Surgery from St. Mary’s Hospital Medical School of the University of London. He received the Cheadle Gold Medal in Medicine for research work with Professor Sir William S. Peart. He has published extensively in the areas of experimental therapeutics and clinical medicine and is currently the Section Editor Translational Therapeutics for the British Journal of Cancer. His current research includes work on genomic and expression mRNA changes in relation to disease and treatment optimization and defining the optimal clinical use for Herceptin and Avastin in breast cancer.
| 